AMYOTROPHIC LATERAL SCLEROSIS research hub

RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 TRIAL OF TRIUMEQ IN AMYOTROPHIC LATERAL SCLEROSIS - LIGHTHOUSE II

This study is looking at a medicine called Triumeq for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease. Researchers want to see if Triumeq can help people live longer and improve their daily lives. We are comparing it to a dummy pill to see how well it works.

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

This study is testing a new medicine called VTx-002 for people with Motor Neurone Disease (ALS). It aims to see if it's safe and how well people can cope with it. Researchers will also look at how it affects the disease over five years.

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

This study is testing a new medicine called AMX0035 for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if it's safe and can help slow down the disease over 48 weeks compared to a dummy medicine.

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

This study, called FUSION, is looking at a new medicine called ION363 for people with a specific type of Motor Neurone Disease (MND) called FUS-ALS. It aims to see if ION363 can help with symptoms and survival for those with a particular gene change.

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

This study is looking at a new medicine called QRL-201 for people with Amyotrophic Lateral Sclerosis (ALS). Researchers want to see if it's safe and how well people tolerate different doses. It's an early-stage study to understand the medicine better.

Therapeutic approach of repeated transient blood-brain barrier opening in amyotrophic lateral sclerosis

This study is looking at a new way to treat motor neurone disease (ALS). It uses sound waves to briefly open the brain's protective barrier, hoping to let medicines work better. Researchers want to see if this method is safe and if it could help patients.

A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)

This study is testing a new drug called masitinib for people with Motor Neurone Disease (ALS). It compares masitinib with a dummy pill (placebo) alongside standard treatment to see if it's safe and helps slow down the disease.

Phase 1/2 Investigation Of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (PIONEER-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002.

This study is testing a new experimental treatment for Motor Neurone Disease (ALS) called VTx-002. It's an early-stage trial (Phase 1/2) focused on checking if the treatment is safe and what side effects it might have. Researchers also want to see if it shows any early signs of helping people.

Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis

This study looks at a new device called SleepImage to see how well it can spot breathing problems in people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease (MND). The goal is to find the best way to know when someone might need help with their breathing, like a special machine called a ventilator.

A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS

A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

This study is looking at a new medication, dazucorilant, for people with Amyotrophic Lateral Sclerosis (ALS). Researchers want to see if it's safe and helps improve symptoms. It involves different doses and aims to understand how the drug works and how well it's tolerated by patients.